Synthesis of Chiral 3-Substituted Phthalides via Rhodium(I)-catalyzed Crossed Alkyne Cyclotrimerisation

Abstract

3-Substituted phthalides were synthesized for the first time by crossed alkyne cyclotrimerisations with Wilkinson’s catalyst. Esterification of propiolic acids with chiral propargylic alcohols by either the DCC/DMAP or the Mitsunobu method allows the synthesis of either enantiomeric form of diyne esters, that are used in crossed alkyne cyclotrimerisations with acetylene to provide 3-substituted phthalides in both enantiomeric forms.

Key words

phthalides - alkyne cyclotrimerisation - Wilkinson’s catalyst - propargylic alcohols - (S)-3-n-butylphthalide

References

• 1a Devon TK. Scott AI. Handbook of Naturally Occurring Compounds   Vol. 1:  Academic Press; New York: 1975.  p.249-264  
• 1b Barry RD. Chem. Rev.  1964,  64:  229 
• Several pharmacological effects ranging from anti-tumor, anti-asthmatic, anti-convulsant, anesthesia prolongation, PGF_{2 α} inhibition, and cerebral anti-ischemic action have been attributed to 3-n-butylphthalides, see for example:
• 2a Zheng GQ. Zhang J. Kenney PM. Lam LKT. ACS Symp. Ser.  1994,  546:  230 
• 2b Zheng GQ. Kenney PM. Zhang J. Lam LK. Nutr. Cancer  1993,  19:  77 
• 2c Liu Z. Song Y. Wang W. Chen W. Wang X. Zhongcaoyao  1982,  13:  17 
• 2d Yu S. You S. Chen H. Yaoxue Xuebao  1984,  19:  486 ; Chem. Abstr. 1984, 101, 222490c
• 2e Sato H. Yorozu H. Yamaoka S. Biomed. Res.  1993,  14:  385 
• 2f Ogawa Y, Hosaka K, Kubota K, and Chin M. inventors; JP  0477480.  ; Chem Abstr. 1992, 117, 69721n
• 2g Wang XW. Drugs Future  2000,  25:  16 
• 3a Tang W. Eisenbrand G. Chinese Drugs of Plant Origin, Chemistry, Pharmacology, and Use in Traditional and Modern Medicine   Springer-Verlag; Berlin, Heidelberg: 1992. 
• 3b Barton DHR. de Vries JX. J. Chem. Soc.  1963,  1916 
• 3c Bjeldanes LF. Kim I.-S. J. Org. Chem.  1977,  42:  2333 
• 3d Bartschat D. Beck T. Mosandl A. J. Agric. Food. Chem.  1997,  45:  4554 
• 4a Ke Y. Ye K. Grossniklaus HE. Archer DR. Joshi HC. Kapp JA. Cancer Immunol. Immunother.  2000,  49:  217 
• 4b Ye K. Ke Y. Keshava N. Shanks J. Kapp JA. Tekmal RR. Petros J. Joshi HC. Proc. Natl. Acad. Sci. U.S.A.  1998,  95:  1601 
• 4c Mehta AK. Ticku MK. Brain Res. Rev.  1999,  29:  196 
• 4d Kardos J. Blandl T. Luyen ND. Doernyei G. Gács-Baitz E. Simonyi M. Cash DJ. Blaskó G. Szántay C. Eur. J. Med. Chem.  1996,  31:  761 
• 4e Prager RH. Tippett JM. Ward AD. Aust. J. Chem.  1981,  34:  1085 
• 4f Hung TV. Mooney BA. Prager RH. Tippett JM. Aust. J. Chem.  1981,  34:  383 
• 5a Sartori G. Bigi F. Tao X. Porta C. Maggi R. Predieri G. Lanfranchi M. Pellinghelli MA. J. Org. Chem.  1995,  60:  6588 
• 5b Taunton J. Wood JL. Schreiber SL. J. Am. Chem. Soc.  1993,  115:  10378 
• 5c Katsuura K. Snieckus V. Can. J. Chem.  1987,  65:  124 
• 5d Katsuura K. Snieckus V. Tetrahedron Lett.  1985,  26:  9 
• 5e Uemura M. Take K. Isobe K. Minami T. Hayashi Y. Tetrahedron  1985,  41:  5771 
• 5f Uemura M. Take K. Hayashi Y. J. Chem. Soc., Chem. Commun.  1983,  858 
• 5g Broadhurst MJ. Hassall CH. J. Chem. Soc., Perkin Trans. 1  1982,  2227 
• 5h Snieckus V. Heterocycles  1980,  14:  1649 
• 5i Kim KS. Spatz MW. Johnson F. Tetrahedron Lett.  1979,  20:  331 
• Aryllithium reagents:
• 6a Takahashi H. Tsubuki T. Higashiyama K. Chem. Pharm. Bull.  1991,  39:  3136 
• 6b Alexakis A. Sedrani R. Normant JF. Mangeney P. Tetrahedron: Asymmetry  1990,  1:  283 
• 6c Ogawa Y. Hosaka K. Chin M. Mitsuhashi H. Heterocycles  1989,  29:  865 
• 6d Meyers AI. Hanagan MA. Trefonas LM. Baker RJ. Tetrahedron  1983,  39:  1991 
• 6e Asami M. Mukaiyama T. Chem. Lett.  1980,  17 
• 6f Dialkyl- and arylzinc reagents: Ogawa Y. Saiga A. Mori M. Shibata T. Takagi K. J. Org. Chem.  2000,  65:  1031 
• 6g See also: Nakano H. Kumagai N. Matsuzaki H. Kabuto C. Hongo H. Tetrahedron: Asymmetry  1997,  8:  1391 
• 6h See further: Soai K. Hori H. Kawahara M. Tetrahedron: Asymmetry  1991,  2:  253 
• 6i See also: Watanabe M. Hashimoto N. Araki S. Butsugan Y. J. Org. Chem.  1992,  57:  742 
• 6j Organotitanium reagents: Takahashi H. Tsubuki T. Higashiyama K. Synthesis  1992,  681 
• 6k Another example: Olivero AG. Weidmann B. Seebach D. Helv. Chim. Acta  1981,  64:  2485 
• 6l Borane reagents: Ramachandran PV. Chen G.-M. Brown HC. Tetrahedron Lett.  1996,  37:  2205 
• BINAP-Ru(II) hydrogenation:
• 7a Kitamura M. Ohkuma T. Inoue S. Sayo N. Kumobayashi H. Akutagawa S. Ohta T. Takaya H. Noyori R. J. Am. Chem. Soc.  1988,  110:  629 
• 7b Ohkuma T. Kitamura M. Noyori R. Tetrahedron Lett.  1990,  31:  5509 
• 7c Transfer hydrogenation: Everaere K. Scheffler J.-L. Mortreux A. Carpentier J.-F. Tetrahedron Lett.  2001,  42:  1899 
• 7d Ni-catalyzed cross couplings: Lei J.-G. Hong R. Yuan S.-G. Lin G.-Q. Synlett  2002,  927 
• 7e Bioreduction: Kitayama T. Tetrahedron: Asymmetry  1997,  8:  253 
• 8a Padwa A. Weingarten MD. J. Org. Chem.  2000,  65:  3722 
• 8b Harland PA. Hodge P. Synthesis  1982,  223 
• 8c Becher J. Nielsen HC. Jacobsen JP. Simonsen O. Clausen H. J. Org. Chem.  1988,  53:  1862 
• 9 Sato Y. Ohashi K. Mori M. Tetrahedron Lett.  1999,  40:  5231 
• 10 Bhatarah P. Smith EH. J. Chem. Soc., Perkin Trans. 1  1992,  2163 
• 11 Müller E. Synthesis  1974,  761 
• 12a Grigg R. Scott R. Stevenson P. Tetrahedron Lett.  1982,  23:  2691 
• 12b Grigg R. Scott R. Stevenson P. J. Chem. Soc., Perkin Trans. 1  1988,  1357 
• 12c Grigg R. Sridharan V. Wang J. Xu J. Tetrahedron  2000,  56:  8967 
• 13a Magnus P. Witty D. Stamford A. Tetrahedron Lett.  1993,  34:  23 
• 13b McDonald FE. Zhu HYH. Holmquist CR. J. Am. Chem. Soc.  1995,  117:  6605 
• 13c Witulski B. Stengel T. Angew. Chem. Int. Ed.  1999,  38:  2426 
• 13d Witulski B. Stengel T. Fernández-Hernández JM. Chem. Commun.  2000,  1965 
• 13e Kotha S. Mohanraja K. Chem. Commun.  2000,  1909 
• 13f McDonald FE. Smolentsev V. Org. Lett.  2002,  4:  745 
• 13g Witulski B. Alayrac C. Angew. Chem. Int. Ed.  2002,  41:  3281 
• 14a Propargylic alcohol (S)-2h (94% ee) is commercially available. The product, (S)-2g was obtained with 88% ee after (S)-alpine borane reduction of the corresponding ketone as described in the literature: Overman LE. Bell KL. J. Am. Chem. Soc.  1981,  103:  1851 
• 14b For the synthesis of (+)-propargylic alcohols via addition of lithium acetylide to aldehydes, see: Midland MM. J. Org. Chem.  1975,  40:  2250 
• For recent achievements in the synthesis of optical active propargylic alcohols, see:
• 15a Franz DE. Tomooka CS. Fässler R. Carreira EM. Acc. Chem. Res.  2000,  33:  373 
• 15b Schubert T. Hummel W. Müller M. Angew. Chem. Int. Ed.  2002,  41:  634 
• 16a Birtwistle DH. Brown JM. Foxton MW. Tetrahedron  1988,  44:  7309 
• 16b Maier S. Kazmaier U. Eur. J. Org. Chem.  2000,  1241 
• For reviews on the Mitsunobu reaction, see:
• 18a Dodge JA. Nissen JS. Presnell M. Org. Synth.  1996,  73:  110 
• 18b Hughes DL. Org. Prep. Proced. Int.  1996,  28:  127 
• 18c Hughes DL. Org. React.  1992,  42:  335 
• 18d Castro BR. Org. React.  1983,  29:  1 
• 18e Mitsunobu O. Synthesis  1981,  1 

17

Selected data for diyne esters 3:
3a: Mp: 101-103 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.99-7.94 (m, 1 H), 7.79-7.74 (m, 3 H), 7.64-7.59 (m, 1 H), 7.40-7.20 (m, 4 H), 5.06 (s, 2 H), 2.97 (s, 1 H), 2.33 (s, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 151.9, 145.4, 134.7, 134.0, 130.5, 130.0, 129.9, 126.9, 125.5, 123.8, 120.4, 113.5, 103.7, 85.9, 78.9, 75.9, 73.9, 54.4, 21.5. MS (EI):
m/z (%) = 377 (100) [M⁺]. Anal. Calcd for C₂₁H₁₅NO₄S: C, 66.83; H, 4.01; N, 3.71. Found: C, 66.99; H, 3.99; N, 3.60.
(S)-3g: ¹H NMR (400 MHz, CDCl₃): δ = 5.40 (dt, J = 6.7 Hz, J = 2.2 Hz, 1 H), 2.93 (s, 1 H), 2.52 (d, J = 2.2 Hz, 1 H), 1.87-1.81 (m, 2 H), 1.49-1.26 (m, 4 H), 0.93 (t, J = 7.2 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃) δ = 151.6, 80.0, 75.4, 74.6, 74.3, 65.9, 34.1, 26.9, 22.1, 13.8. MS (EI): m/z (%) = 164 (8) [M⁺].
(S)-3i: Mp: 59-61 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.61-7.58 (m, 2 H), 7.48-7.43 (m, 1 H), 7.40-7. 35 (m, 2 H), 5.56 (dq, J = 6.6, J = 2.2 Hz, 1 H), 2.53 (d, J = 2.2 Hz, 1 H), 1.60 (d, J = 6.6 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 152.8, 133.0, 130.8, 128.6, 119.4, 87.1, 81.2, 80.2, 73.8, 61.7, 21.1. MS (EI): m/z (%) = 198(7) [M⁺]. Anal. Calcd for C₁₃H₁₀O₂: C, 78.77; H, 5.09. Found: C, 78.82; H, 4.98.

19

The enantiopurity of the esters 3g-i was analyzed after their conversion to the phthalides 4f-h, that proceeded without any detectable racemisation.

20

Selected data for phthalides 4:
(S)-4f: Oil; [α]_D ²² = -42 (c 0.45, CHCl₃); 88% ee as determined by chiral capillary GLC analysis with Supleco Beta-Dex^{Τ Μ} 325; {lit. [6l] [α]_D ²² -62 (c 0.42, CHCl₃)}. ¹H NMR (400 MHz, CDCl₃): δ = 7.89 (d, J = 7.6 Hz, 1 H), 7.67 (dt, J = 7.6 Hz, J = 3.3 Hz, 1 H), 7.52 (t, J = 7.6 Hz, 1 H), 7.46 (d, J = 7.6 Hz, 1 H), 5.49 (dd, J = 7.9 Hz, J = 4.1 Hz, 1 H), 2.10-2.01 (m, 1 H), 1.81-1.71 (m, 1 H), 1.53-1.33 (m, 4 H), 0.88 (t, J = 7.2 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 170.5, 150.0, 133.8, 128.9, 126.0, 125.5, 121.7, 81.3, 34.3, 26.7, 22.3, 13.7. MS (EI): m/z (%) = 190(5) [M⁺].
(S)-4g: oil; [α]_D ²² = -22.1 (c 0.83, MeOH); 94% ee as determined by chiral capillary GLC analysis with Supleco Beta-Dex^{Τ Μ} 325. (R)-4g: [α]_D ²² = +21.4 (c 0.81, MeOH); 94% ee as determined by chiral capillary GLC analysis with Supleco Beta-Dex^{Τ Μ} 325.
(S)-4h: [α]_D ²² = -15.6 (c 0.94, CHCl₃). (R)-4h: [α]_D ²² = +14.9 (c 0.98, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ = 7.71 (t, J = 7.6 Hz, 1 H), 7.58-7. 55 (m, 2 H), 7.50-7.41 (m, 5 H), 5.56 (q, J = 6.6 Hz, 1 H), 1.69 (d, J = 6.6 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 152.5, 142.7, 136.4, 133.8, 130.8, 129.5, 128.3, 127.9, 121.8, 120.3, 76.1, 20.6. MS (EI): m/z (%) = 224(100) [M⁺].